

# Clinical Oversight Review Board (CORB) Criteria for Prescribing Belimumab intravenous (Benlysta)

## Notes:

- Quantity Limits: No
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Non-Formulary **belimumab intravenous (Benlysta)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

## **Initiation (new start) criteria and for *new members* entering Kaiser Permanente already taking the medication who have not been reviewed previously:**

1. Prescriber is a rheumatologist and patient has a diagnosis of active systemic lupus erythematosus (SLE)
  - Patient is 5 years of age or older
  - Patient has positive antinuclear antibody (ANA), anti-double-stranded deoxyribonucleic acid (anti-dsDNA), and/or Sjogren's antibody (SSA or SSB)
  - Patient is dependent on corticosteroid therapy OR documented contraindication or intolerance to corticosteroid therapy
  - Patient has a documented treatment failure (at least a 60-day course) or contraindication/intolerance to all of the following:
    - At least one nonsteroidal anti-inflammatory (NSAID) medication (e.g. aspirin, ibuprofen, naproxen, etodolac, meloxicam)
    - At least one antimalarial (e.g. hydroxychloroquine, chloroquine)
    - At least one immunomodulator (e.g. cyclophosphamide, azathioprine, methotrexate, mycophenolate)
2. Prescriber is a rheumatologist and patient has a diagnosis of active lupus nephritis (LN)
  - Patient is 5 years of age or older
  - Patient has positive antinuclear antibody (ANA), anti-double-stranded deoxyribonucleic acid (anti-dsDNA), and/or Sjogren's antibody (SSA or SSB)
  - Patient is dependent on corticosteroid therapy OR documented contraindication or intolerance to corticosteroid therapy
  - Patient has a documented treatment failure (at least a 60-day course) or contraindication/intolerance to all of the following:

kp.org

Revised: 08/10/23  
Effective: 10/05/23

All plans offered and underwritten by  
Kaiser Foundation Health Plan of the Northwest

# Clinical Oversight Review Board (CORB) Criteria for Prescribing Belimumab intravenous (Benlysta)

- At least one nonsteroidal anti-inflammatory (NSAID) medication (e.g. aspirin, ibuprofen, naproxen, etodolac, meloxicam)
- At least one antimalarial (e.g. hydroxychloroquine, chloroquine)
- At least one immunomodulator (e.g. cyclophosphamide, azathioprine, methotrexate, mycophenolate)
- Tacrolimus

[kp.org](http://kp.org)

Revised: 08/10/23  
Effective: 10/05/23

All plans offered and underwritten by  
Kaiser Foundation Health Plan of the Northwest